58.79

7.04% -4.45

After Hours: 59.38 0.59 +1.00%

Exact Sciences Corp. (EXAS)

Overview News Price History Option Chain Discussions Forecast

Exact Sciences Corp. stock is currently priced at $58.79, with a 24-hour trading volume of 2.65M. It has seen a -7.04% decreased in the last 24 hours and a -7.79% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $63.58 pivot point. If it approaches the $61.82 support level, significant changes may occur.

Previous Close:

$63.24

Open:

$62.17

24h Volume:

2.65M

Market Cap:

$10.67B

Revenue:

$2.50B

Net Income/Loss:

$-204.15M

P/E Ratio:

-37.08

EPS:

-1.5857

Net Cash Flow:

$31.93M

1W Performance:

-7.39%

1M Performance:

-7.79%

6M Performance:

-4.89%

1Y Performance:

-7.49%

1D Range:

$58.40

$62.50

52W Range:

$56.05

$100.77

Exact Sciences Corp. Stock (EXAS) Company Profile

Name

Exact Sciences Corp.

Sector

Healthcare (1197)

Industry

Diagnostics & Research (66)

Phone

608-284-5700

Address

441 Charmany Drive, Madison, WI

Employee

1,268

Twitter

@exactsciences

Next Earnings Date

2024-05-08

Latest SEC Filings

EXAS's Discussions on Twitter

Exact Sciences Corp. Stock (EXAS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-02-24	Upgrade	The Benchmark Company	Hold → Buy
Dec-14-23	Initiated	Guggenheim	Buy
Dec-13-23	Initiated	Wolfe Research	Outperform
Oct-10-23	Upgrade	Piper Sandler	Neutral → Overweight
Sep-28-23	Initiated	Bernstein	Outperform
Aug-02-23	Downgrade	The Benchmark Company	Buy → Hold
May-10-23	Upgrade	Craig Hallum	Hold → Buy
May-05-23	Initiated	UBS	Neutral
Mar-09-23	Upgrade	Citigroup	Neutral → Buy
Feb-10-23	Downgrade	Credit Suisse	Outperform → Neutral
Jan-18-23	Downgrade	Raymond James	Outperform → Mkt Perform
Oct-19-22	Downgrade	Craig Hallum	Buy → Hold
Aug-25-22	Initiated	Credit Suisse	Outperform
Jun-03-22	Initiated	Piper Sandler	Neutral
Nov-03-21	Downgrade	Raymond James	Strong Buy → Outperform
Jul-29-21	Reiterated	BTIG Research	Buy
Jul-29-21	Reiterated	Canaccord Genuity	Buy
Jul-29-21	Reiterated	Oppenheimer	Outperform
Jul-29-21	Reiterated	Stifel	Buy
Jun-15-21	Initiated	Raymond James	Strong Buy
Jun-03-21	Initiated	Goldman	Buy
May-25-21	Initiated	Wells Fargo	Equal Weight
Jan-28-21	Initiated	Truist	Buy
Oct-29-20	Downgrade	UBS	Buy → Neutral
Oct-28-20	Downgrade	Citigroup	Buy → Neutral
Oct-08-20	Resumed	BTIG Research	Buy
Apr-02-20	Initiated	Evercore ISI	Outperform
Jan-10-20	Resumed	BTIG Research	Buy
Jan-07-20	Initiated	Citigroup	Buy
Dec-13-19	Initiated	Dougherty & Company	Buy
Nov-15-19	Initiated	Stifel	Buy
Oct-17-19	Reiterated	BofA/Merrill	Buy
Oct-01-19	Resumed	Craig Hallum	Buy
Sep-26-19	Initiated	Oppenheimer	Outperform
Feb-26-19	Upgrade	Goldman	Neutral → Buy
Oct-09-18	Initiated	UBS	Buy
Sep-05-18	Resumed	The Benchmark Company	Hold
Aug-13-18	Reiterated	Canaccord Genuity	Buy
Apr-03-18	Upgrade	BTIG Research	Neutral → Buy
Jan-29-18	Initiated	Goldman	Neutral
Jan-08-18	Reiterated	The Benchmark Company	Buy
Nov-13-17	Downgrade	Robert W. Baird	Outperform → Neutral
Nov-01-17	Downgrade	BTIG Research	Buy → Neutral

View All

Exact Sciences Corp. Stock (EXAS) Latest News

Exact Sciences Corp. Stock (EXAS) Financials Data

Exact Sciences Corp. (EXAS) Revenue 2024

EXAS reported a revenue (TTM) of $2.50 billion for the quarter ending December 31, 2023, a +19.93% rise year-over-year.

Exact Sciences Corp. (EXAS) Net Income 2024

EXAS net income (TTM) was -$204.15 million for the quarter ending December 31, 2023, a +67.26% increase year-over-year.

Exact Sciences Corp. (EXAS) Cash Flow 2024

EXAS recorded a free cash flow (TTM) of $31.93 million for the quarter ending December 31, 2023, a +107.29% increase year-over-year.

Exact Sciences Corp. (EXAS) Earnings per Share 2024

EXAS earnings per share (TTM) was -$1.1357 for the quarter ending December 31, 2023, a +67.92% growth year-over-year.

Exact Sciences Corp. Stock (EXAS) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Baranick Brian	EVP, GM., Precision Oncology	Apr 02 '24	Sale	79.43	924	73,393	13,171
Condella Sarah	EVP, Human Resources	Apr 01 '24	Sale	70.00	2,000	140,000	71,787
Condella Sarah	EVP, Human Resources	Mar 28 '24	Sale	70.00	2,000	140,000	73,787
Conroy Kevin T	President and CEO	Mar 01 '24	Sale	59.32	8,271	490,636	1,299,496
LEVANGIE DANIEL J	Director	Mar 01 '24	Sale	57.50	5,000	287,500	22,975
Cunningham Everett	Chief Commercial Officer	Mar 01 '24	Sale	59.32	2,412	143,080	46,179
Elliott Jeffrey Thomas	Chief Financial Officer	Mar 01 '24	Sale	59.32	2,412	143,080	10,933
Baranick Brian	Gen. Mgr., Precision Oncology	Mar 01 '24	Sale	59.32	2,323	137,800	14,095
ORVILLE JACOB A	General Manager, Screening	Mar 01 '24	Sale	59.32	2,154	127,775	14,324
Doyle James Edward	Director	Mar 01 '24	Sale	57.50	2,000	115,000	50,110

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.